Santen

Eyevance Pharmaceuticals LLC focuses on the development and commercialization of ophthalmic products aimed at addressing significant unmet medical needs in ocular health. Based in Fort Worth, Texas, the company offers a range of therapies, including TOBRADEX ST for steroid-responsive inflammatory ocular conditions, ZERVIATE for severe ocular itch, FLAREX for anterior segment inflammation, NATACYN for fungal infections, and FRESHKOTE for dry eye symptoms. Established in 2017, Eyevance aims to enhance patients' vision and quality of life through innovative topical ophthalmic solutions. The company operates as a subsidiary of Santen Holdings U.S. Inc.

Plano Pte Ltd. develops software application to manage mobile device usage for children. The product can be used by parents to track the smart device usage of their children and restrict it to prevent them from risk of eye strain and myopia. Plano Pte Ltd. was founded in 2017 and is based in Singapore.

QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrate for various applications in communications and industry. The company produces a range of products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, it offers broadband gain chips for ophthalmic testing equipment and retinal imaging laser eyewear. QD Laser's technology is applied in areas such as silicon photonics, sensing, and precision machining. The company serves a diverse clientele across telecommunications, manufacturing, medicine, and consumer products. Established in 2006, QD Laser is headquartered in Kawasaki, Japan.

QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrate for various applications in communications and industry. The company produces a range of products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, it offers broadband gain chips for ophthalmic testing equipment and retinal imaging laser eyewear. QD Laser's technology is applied in areas such as silicon photonics, sensing, and precision machining. The company serves a diverse clientele across telecommunications, manufacturing, medicine, and consumer products. Established in 2006, QD Laser is headquartered in Kawasaki, Japan.

International Biomedical Devices (IBMD) is an early-stage medical device company focused on ophthalmology innovations. At present, the company is leading the emerging, non-laser based, precision capsulotomy category through the development of a unique and much-needed new capsulotomy technology. It was founded in 2013 and is based in Charleston, South Carolina.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

TearSolutions, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for dry eye conditions. Founded in 2013, the company's primary product is Lacripep, a synthetic peptide derived from the natural tear protein lacritin, designed as a topical treatment for dry eyes. TearSolutions is currently advancing Lacripep through phase II human clinical trials, aiming to establish it as a novel replacement therapy. The company employs an outsourcing model to enhance its research and development efforts, reflecting its commitment to providing effective medical solutions for individuals suffering from dry eye syndrome.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for serious eye diseases. Founded in 2011 and based in Alpharetta, Georgia, the company utilizes a proprietary ocular microinjection platform to deliver therapies directly to specific compartments of the eye, including the retina and choroid. Its lead product, XIPERE, is a suprachoroidal injectable suspension of triamcinolone acetonide, targeting macular edema associated with conditions such as uveitis and diabetic macular edema. Additionally, Clearside is advancing CLS-AX, an axitinib formulation for suprachoroidal injection. The company's novel SCS Microinjector allows for a non-surgical, repeatable procedure aimed at preserving and restoring vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for serious eye diseases. Founded in 2011 and based in Alpharetta, Georgia, the company utilizes a proprietary ocular microinjection platform to deliver therapies directly to specific compartments of the eye, including the retina and choroid. Its lead product, XIPERE, is a suprachoroidal injectable suspension of triamcinolone acetonide, targeting macular edema associated with conditions such as uveitis and diabetic macular edema. Additionally, Clearside is advancing CLS-AX, an axitinib formulation for suprachoroidal injection. The company's novel SCS Microinjector allows for a non-surgical, repeatable procedure aimed at preserving and restoring vision in patients with sight-threatening eye diseases.